Armata Pharmaceuticals (ARMP) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Coherus Oncology (CHRS) over the past year, gaining 19.9% versus a loss of 39.2%. Over five years, ARMP leads with a +11.9% price change compared with -93.7% for CHRS. Coherus Oncology is the larger company by market cap ($170.0 million vs $142.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | CHRS |
|---|---|---|
| Share price | $3.83 | $1.10 |
| Market cap | $142.41M | $169.95M |
| 1-day change | -0.78% | +2.82% |
| YTD return | -38.54% | -24.65% |
| 1-year return | +19.88% | -39.20% |
| 5-year return | +11.88% | -93.71% |
| EPS (TTM) | $-5.29 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $2.62 |
| 52-week low | $3.14 | $0.974 |
| Distance from 52-week high | -76.56% | -57.95% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +356.92% | +604.55% |
| Average volume | 208.13K | 1.16M |
| Shares outstanding | 37.18M | 154.50M |
| Employees | 61 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed CHRS by 59.1 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
ARMP vs CHRS FAQ
Which is bigger, Armata Pharmaceuticals or Coherus Oncology?
Coherus Oncology (CHRS) is larger, with a market capitalization of $169.95M compared with $142.41M for Armata Pharmaceuticals (ARMP).
Which stock has performed better over the past year, ARMP or CHRS?
ARMP returned +19.88% over the past 12 months, compared with -39.20% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Coherus Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.